The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

Indian paediatric rheumatologists discuss early diagnosis and management of rheumatic disorders in children to prevent organ ...

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...

Research analysts at HC Wainwright raised their Q1 2025 EPS estimates for shares of Cabaletta Bio in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst D. Tsao now anticipates ...

Cabaletta Bio (NASDAQ:CABA – Get Free Report) had its price target cut by equities research analysts at Morgan Stanley from ...

Bringing Expert Dermatology Care Closer to Our Patients Our expansion to Smithfield allows us to serve more patients with advanced ...

Mar. 25, 2025 — A drug typically prescribed for arthritis halts brain-damaging seizures in mice that have a condition like epilepsy, according to researchers. If the drug proves viable for human ...

Objectives Myositis is a heterogeneous family of diseases including dermatomyositis (DM), immune-mediated necrotising myopathy (IMNM), antisynthetase syndrome (AS) and inclusion body myositis (IBM).